-
Mashup Score: 3A Systematic Review of Treatment Strategies in VEXAS Syndrome - ACR Meeting Abstracts - 6 hour(s) ago
Background/Purpose: VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome, first described in 2020, is an autoinflammatory condition characterized by somatic mutations in the UBA1 gene. Predominantly affecting elderly males, VEXAS syndrome manifests with systemic inflammation and refractory hematologic abnormalities. Despite advancements in our understanding of this condition over the last 4 years, treatment recommendations for […]
Source: acrabstracts.orgCategories: General Medicine News, RheumatologyTweet
Most common treatments in #VEXAS 🔹IL-6 inhibitors 🔹IL-1 inhibitors 🔹JAK inhibitors 🔹Azacitidine 🔹Glucocorticoid monotherapy Few reports on 🔸Rituximab, Secukinumab, Abatacept, Hydroxychloroquine, Cyclophosphamide #ACR24 #ACR2024 abstract 2032 👉🏽https://t.co/hOWYDsTg4D https://t.co/X726Y2qS7T